Cypherpunk e o rali de privacidade que sacudiu o mercado - Webitcoin Cypherpunk injeta US$ 50 mi em Zcash, acende rali explosivo e reacende a era das criptos focadas em privacidade.

💥 #Cypherpunk (ex- #LeapTherapeutics) investe US$ 50 mi em #Zcash ( #ZEC) c/apoio dos #Winklevoss. Token salta +800% 📈e ações +440% 🚀. Aposta reacende o debate sobre #privacidade🌐e #autossoberania💫no #mercadocripto

#tesourariadeativosdigitais #webitcoin
webitcoin.com.br/cypherpunk-e...

🚨 ALERTA: Leap Therapeutics sube 25% tras acuerdo de inversión cripto por $59M liderado por Winklevoss Capital. El capital se destinará a investigación oncológica y tokenización de activos biomédicos. #Criptomonedas #LeapTherapeutics #Winklevoss

Leap Therapeutics stock jumps after announcing strategic review process Investing.com -- Leap Therapeutics Inc (NASDAQ:LPTX) stock surged 9% following the company’s announcement of a strategic review process to maximize shareholder value amid ongoing financial constraints. The clinical-stage biotechnology company reported it has engaged Raymond James & Associates as its exclusive financial advisor to explore strategic alternatives, including potential sale or partnership opportunities for its drug candidates sirexatamab and FL-501, as well as leveraging its cash balance of $32.7 million as of March 31, 2025. Leap also disclosed plans to implement a significant workforce reduction of approximately 75% over the next two months as its DeFianCe study completes. The restructuring is expected to cost around $3.2 million, with most expenses recognized in the third quarter of 2025. "Due to current market conditions, we have decided to wind-down the DeFianCe clinical trial and further reduce internal expenses. In parallel, we have initiated a review of the full range of strategic alternatives to maximize shareholder value," said Douglas E. Onsi, President and Chief Executive Officer of Leap. The company reported updated results from Part B of its DeFianCe study, noting that sirexatamab demonstrated statistically significant benefits in specific patient subgroups with high levels of DKK1, no prior exposure to anti-VEGF therapy, or liver metastasis. The company believes the objectives of the study have been achieved with the additional patient follow-up. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Click Subscribe #LeapTherapeutics #StockMarket #Investing #StrategicReview #FinanceNews